Recombinant DNA Technology Market

Recombinant DNA Technology Market: Overview

The market size for Recombinant DNA Technology was USD 141.2 million in 2021, projected to grow at a CAGR of 7.7 percent during the forecast period. Some primary factors affecting the market's growth are exceptional developments in treating fatal human ailments such as infectious diseases, diabetes, and cancer. Recombinant technology developments have aided the development of gene therapy, long-acting therapeutic proteins for drugs, and cutting-edge molecular medicine. It is projected that increasing developments and positive effects on the treatment of genetic disorders would stimulate the rise.

Recombinant DNA technology in agriculture is projected to propel market expansion. One of the main factors influencing the segment's growth is initiatives taken by both governmental and private organizations. For instance, in August 2021, Corteva Inc. introduced the genetically altered Conkesta E3 soybean seed in the Brazilian market. The European Union Commission has approved the soybeans, allowing grain produced from Brazilian-grown Conkesta E3 soybean seeds to be exported to Europe for use as food and feed.

One of the main drivers of market expansion is the advancement of treatment methods brought on by the development of diagnostic tools, monitoring systems, and novel therapy techniques. Another element propelling the market's growth is the introduction of new products. For instance, in September 2021, researchers from the University of Tsukuba teamed up with a Tokyo start-up company named Sanatech Seed Co. to use CRISPR/Cas9 gene-editing technology to create a new type of tomatoes. The first available products were seeds, distributed gratis to about 4,200 people. The business has begun marketing genetically altered tomatoes. Such launches will accelerate the market's growth in the foreseeable future.

Recombinant DNA Technology Market: COVID-19 Impact

The COVID-19 pandemic has impacted several global sectors, and the global market for recombinant DNA technology is no exception. Governments put in place several measures, such as a rigorous lockdown, to preserve social distance norms and slow the pandemic's rapid spread. The global manufacturing facilities were forced to close during the pandemic's early phases, which adversely affected the recombinant DNA technology market. The pandemic directly impacted small and medium-sized businesses, the Recombinant DNA Technological Market industry's main technology suppliers. Additionally, the industry rollout for recombinant DNA technology is considered as the pandemic's effects fade progressively around the beginning of 2022.

Recombinant DNA Technology Market: Drivers

Rising Technological Advancements within R&D Initiatives to Drive Market Growth

The boom aids the production of fresh products in technological advancements. The Recombinant DNA Technology Market is also growing due to increased research and development efforts for treating serious illnesses, including cancer, diabetes, and other immunodeficiency disorders. The combination of technology and medicine makes it possible to treat diseases by replacing faulty or sick genes in a patient's body with newer, healthy ones. Additionally, the development of gene therapy as a result of recombinant technology improvements has been employed to cure hereditary illnesses. This will support the Global Recombinant DNA Technology Market's expansion throughout the projection.

Additionally, the recombinant DNA technology market enables researchers to treat diabetes by creating human insulin using bacteria as the host cell. This drug is more effective than standard medications because microbes produce it. These developments are therefore projected to aid market expansion in the coming years.

Increasing Strategic Collaborations among Market Players to Drive Market Growth

In the upcoming years, the market's growth is likely to be fueled by increased strategic collaborations between important players in the recombinant DNA technology sector. Top businesses are also collaborating strategically with leading biopharmaceutical firms and academic institutions to develop breakthrough treatments based on the market for recombinant DNA technology. The Recombinant DNA Technology Market will have promising global possibilities in the approaching years because of these industry alliances. In May 2022, the Wellington, New Zealand-based Malaghan Institute of Medical Research announced that as part of its development plans, it would devote USD 40 million over the following four years to creating vaccines.

Recombinant DNA Technology Market: Restraints

High Complexity and Cost to Hamper Market Growth

The development of the recombinant DNA technology market is hampered by the high complexity, the significant investment necessary to establish a manufacturing facility to manufacture recombinant DNA, and the low adoption of genetically modified crops. The high expense of recombinant DNA technology and negative side effects of gene therapies, including Cytokine Release Syndrome (CRS) or neurotoxicities, are factors restraining market expansion. The public occasionally objects to the use of GM products, which also restricts market expansion. The strict rules for product approval in many regions may be another significant barrier. Additionally, the operations' hazards could provide difficulties for the global market. The main players are therefore focusing on these aspects to find the best answer to these difficulties.

Recombinant DNA Technology Market: Segment Overview

Expression Systems Segment to Dominate Market Due to Ongoing Improvements for Effective Protein Expression

Based on product type, the Recombinant DNA Technology market is segmented into recombinant protein drugs, genetically modified crops, expression systems, vaccines, cell and gene therapy and gene editing. The expression systems segment dominates the market and is expected to maintain its dominance over the forecast period. The expression system and cloning vector are the two fundamental parts of this technology. Due to ongoing improvements in effective protein expression and its further isolation on a wide scale, expression systems accounted for the highest proportion. Mammalian, insect, bacterial, and yeast expression systems are the most often utilized. The growth of cell lines like HEK293 and Chinese Hamster Ovarian (CHO) has helped explain why mammals account for a sizable portion of expression systems. In addition, continuing research efforts to study the potential of plants as expression systems are predicted to drive the adoption of plan expression systems for GM product development in the next years. It is understood that cloning vectors serve as the foundation for creating DNA inserts.

Agriculture Category to Dominate Market Owing to Rising Production of Genetically Modified Crops

Based on application, the Recombinant DNA Technology market is segmented into therapeutics, agriculture and research. The agriculture segment dominates the market and is expected to maintain its dominance over the forecast period. A significant amount of public support is being gained for the creation of genetically modified crops in agriculture to increase yield and resistance to pesticides or herbicides. One of the first commercially available genetically engineered crop products to receive a license for human use was the genetically modified tomato, CGN-89564-2. Furthermore, the identification, appraisal, mining, and innovation of plant germplasm resources depend on DNA molecular marker technologies. GMOs in food were made possible by the development of GM fruit. Genetic alteration is currently gaining popularity. Therefore, expanding the use of RDT in agriculture is anticipated to fuel the segment's growth.

Recombinant DNA Technology Market: Regional Landscape

North America to Dominate Market due to Presence of Numerous Biopharmaceutical Manufacturing Companies

Over the forecast period, it is anticipated that the North American market will account for the largest revenue share. The United States holds the largest market share, largely due to the abundance of biopharmaceutical manufacturing businesses and efficient regulatory authorities to keep an eye on the different ethical and scientific worries regarding the use of technology. Especially in North America, this is anticipated to fuel the market's expansion. Several research investigations are fueling the growth of the market. For instance, in September 2021, a research report named "Review of Poultry Recombinant Vector Vaccines" published in the US National Library of Medicine claimed that using several live and inactivated vaccines is crucial for the prevention of poultry diseases.

The European market is anticipated to experience stable revenue growth throughout the forecast period due to government investments in hospitals and other high-quality healthcare services. Additionally, the market is expanding due to the low cost of sequencing, partnerships and collaborations, and the rising demand for the NGS technique from research institutes. The European Medicines Agency's Committee for the Use of Medicinal Products provided VBI Vaccines Inc. with favorable feedback in February 2022. This viewpoint was about the PreHevbri 3-antigen hepatitis B (HBV) vaccine, developed to provide adults with immunity against hepatitis B virus infection. Because hepatitis B is still a concern for public health in Europe, this favorable judgment gave medical professionals a useful tool for preventing patients from contracting the illness.

Global Recombinant DNA Technology Market: Competitive Landscape

In March 2022, to prevent infection by any known subtype of the hepatitis B virus (HBV) in people 18 years of age, VBI Vaccines Inc. introduced PreHevbrio (Recombinant Hepatitis B Vaccine) in the United States. On the other hand, in June 2021, GenScript USA Inc., the world's top provider of life science research equipment and services, introduced the GenWandTM Double-Stranded DNA (dsDNA) Service for manufacturing the CRISPR knock-in homology-directed repair (HDR) templates in T cell engineering. Closed-end dsDNA is helpful for large-scale screening and scaling up in cell and gene therapy. This is because it allows researchers to conduct gene knock-in with lesser toxicity and higher efficiency than typical PCR procedures

A few players in the Recombinant DNA Technology Market include Thermo Fisher Scientific, Inc., Biogen, Inc., Sanofi Pasteur, Merck & Co., Inc., Pfizer, Inc., Profacgen, Amgen, Inc., and Monsanto Company

Regional Classification of the Global Recombinant DNA Technology Market is Described Below:

North America

• U.S.
• Canada

Europe

• Germany
• France
• Spain
• U.K.
• Italy
• Russia
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East and Africa

• GCC
• South Africa
• Rest of Middle East and Africa

*Regions and countries are subject to change based on data availability

Key Elements Included In The Study: Global Recombinant DNA Technology Market

• Recombinant DNA Technology Market by Product/Technology/Grade, Application/End-user, and Region
• Executive Summary (Opportunity Analysis and Key Trends)
• Historical Market Size and Estimates, Value, 2018 - 2022
• Market Value at Regional and Country Level, 2023 - 2030
• Market Dynamics and Economic Overview
• Market Size in Value, Growth Rates, and Forecast Figures, 2023 - 2030
• Competitive Intelligence with Financials, Key Developments, and Portfolio of Leading Companies 
• Regional and Product/Grade/Application/End-user Price Trends Analysis
• Value Chain and Five Force’s Analysis
• Regional/Sub-region/Country Market Size and Trend Analysis
• Company Market Share Analysis and Key Player Profiles

Post Sale Support, Research Updates & Offerings

We value the trust shown by our customers in Fairfield Market Research. We support our clients through our post sale support, research updates and offerings.

• The report will be prepared in a PPT format and will be delivered in a PDF format.

• Additionally, Market Estimation and Forecast numbers will be shared in Excel Workbook.

• If a report being sold was published over a year ago, we will offer a complimentary copy of the updated research report along with Market Estimation and Forecast numbers within 2-3 weeks’ time of the sale.

• If we update this research study within the next 2 quarters, post purchase of the report, we will offer a Complimentary copy of the updated Market Estimation and Forecast numbers in Excel Workbook.

• If there is a geopolitical conflict, pandemic, recession, and the like which can impact global economic scenario and business activity, which might entirely alter the market dynamics or future projections in the industry, we will create a Research Update upon your request at a nominal charge.